Objective – Chronic and acute dysregulation of the cytokine network has been described in multiple sclerosis (MS). Inflammatory lesions in the central nervous system of MS patients can be assessed by ...brain magnetic resonance imaging (MRI). This study has been performed to investigate whether changes of cytokines correlate with morphological changes as determined by MRI. Materials and methods – We included 46 patients with relapsing–remitting MS in the study. The serum concentrations of tumor necrosis factor‐β (TNF‐β), TNF receptor‐1 (TNFR‐1; 55 kDa) and TNFR‐2 (75 kDa), interleukin‐4 (IL‐4), interleukin‐10 (IL‐10) and interferon‐γ (IFN‐γ) were measured by enzyme linked immunosorbent assay in all patients. Each parameter was correlated with clinical findings and brain MRI parameters. We measured both the number (lesion load) and cumulated area (disease burden) of all lesions on brain MRI. In addition, the number and cumulated area of those lesions showing signs of activity Gadolinium (Gd)‐enhancement, perifocal edema were determined. Results – A non‐significant trend (P < 0.05) was found only for the correlation of serum IFN‐γ levels and the number of active MRI lesions showing both Gd‐enhancement and perifocal edema in the subgroup of patients (n=21) with active lesions. When corrected for multiple comparisons, this correlation was not significant anymore, as it was above the corrected P‐value of 0.001. We could not observe any further correlation of cytokine levels and MRI parameters. However, TNF‐β serum levels were significantly (P < 0.05) elevated in the patient subgroups with higher number of lesions and disease burden, respectively. Conclusion – Our data show that the determination of serum levels of the investigated cytokines and cytokine receptors is not useful as a tool to determine subclinical disease activity and severity as assessed by brain MRI.
Background: The expression of soluble cell adhesion molecules (AM) in cerebrospinal fluid (CSF) and blood and their significance as measures of disease activity has been extensively studied in ...patients with multiple sclerosis (MS). In previous studies, we found that cell surface bound AM on mononuclear cells (MNC) in CSF and blood might be useful markers of clinical disease activity in MS patients.
Objective: To analyze the correlation of cell surface bound and soluble AM in CSF and blood with magnetic resonance imaging (MRI) markers of subclinical disease severity and activity in patients with MS.
Methods: Expression levels of cell surface bound AM on peripheral blood and CSF MNC were determined by flow cytometry analysis in 77 (CSF: 33) MS patients. Concentration levels of the soluble forms of AM were measured by enzyme-linked immunosorbent assay (ELISA). In corresponding cerebral gadolinium (Gd)-enhanced MRI scans, we determined both measures of subclinical disease severity and subclinical disease activity.
Results: The expression levels of cell surface bound AM in peripheral blood correlated inversely with parameters for subclinical disease severity and activity on cerebral MRI scans as well as with the disease duration. Furthermore, we found significant correlations between serum levels of soluble AM and patient age but not with disease duration.
Conclusions: Our results suggest that subclinical disease progression may be associated with a decrease of the expression of cell surface bound AM on peripheral blood MNC. This might be a result of activated MNC migration into the CNS.
Objectives– Multiple sclerosis (MS) is believed to be an autoimmune disease of the human central nervous system mediated by autoreactive T cells. Interferon‐β1b (IFN‐β1b) has been shown to be ...effective in reducing disease activity defined by clinical and magnetic resonance imaging (MRI) criteria in relapsing–remitting MS (RRMS). Yet, the exact mechanisms by which these benefits are achieved remain unknown. CD45RA is a marker for naive T lymphocytes and intercellular adhesion molecule‐3 (ICAM‐3) is expressed on resting lymphocytes.
Material and methods– Forty‐eight patients with RRMS, 24 of them treated with recombinant IFN‐β1b and 24 untreated, were enrolled in this prospective study over 18 months. We investigated the percentage of CD45RA+ ICAM‐3+ cells within the total lymphocyte subset in the peripheral blood serially every 3 months and in CSF once at baseline. Detailed clinical examination including Expanded Disability Status Scale (EDSS) score was performed every 3 months and cranial MRI scans were assessed every 6 months.
Results– We found a temporary increase in the CD45RA+ ICAM‐3+ lymphocyte ratio in peripheral blood of both untreated and IFN‐β1b‐treated RRMS patients. Moreover, we determined a significant negative correlation (r = −0.5874; P < 0.01) between age as well as the EDSS score (r = −0.3629; P < 0.05) and the percentages of CD45RA+ ICAM‐3+ lymphocytes in peripheral blood but a positive correlation between EDSS score and the CD45RA+ ICAM‐3+ ratio (r = 0.3913; P < 0.05) in the CSF at baseline.
Conclusion– CD45RA+ ICAM‐3+ lymphocyte ratio in peripheral blood might indicate immunosenescence in MS. However, from our data it cannot be finally concluded whether it is also influenced by IFN‐β1b treatment.
Multiple sclerosis (MS) is believed to be an autoimmune disease of the human central nervous system mediated by autoreactive T cells. Interferon-beta1b (IFN-beta1b) has been shown to be effective in ...reducing disease activity defined by clinical and magnetic resonance imaging (MRI) criteria in relapsing-remitting MS (RRMS). Yet, the exact mechanisms by which these benefits are achieved remain unknown. CD45RA is a marker for naive T lymphocytes and intercellular adhesion molecule-3 (ICAM-3) is expressed on resting lymphocytes.
Forty-eight patients with RRMS, 24 of them treated with recombinant IFN-beta1b and 24 untreated, were enrolled in this prospective study over 18 months. We investigated the percentage of CD45RA+ ICAM-3+ cells within the total lymphocyte subset in the peripheral blood serially every 3 months and in CSF once at baseline. Detailed clinical examination including Expanded Disability Status Scale (EDSS) score was performed every 3 months and cranial MRI scans were assessed every 6 months.
We found a temporary increase in the CD45RA+ ICAM-3+ lymphocyte ratio in peripheral blood of both untreated and IFN-beta1b-treated RRMS patients. Moreover, we determined a significant negative correlation (r = -0.5874; P < 0.01) between age as well as the EDSS score (r = -0.3629; P < 0.05) and the percentages of CD45RA+ ICAM-3+ lymphocytes in peripheral blood but a positive correlation between EDSS score and the CD45RA+ ICAM-3+ ratio (r = 0.3913; P < 0.05) in the CSF at baseline.
CD45RA+ ICAM-3+ lymphocyte ratio in peripheral blood might indicate immunosenescence in MS. However, from our data it cannot be finally concluded whether it is also influenced by IFN-beta1b treatment.
Objectives – To investigate the influence of interferon (IFN) beta‐1b on the serum levels of sTNF‐R1, sTNF‐R2 and TNF‐beta in patients with multiple sclerosis (MS) in correlation with clinical and ...MRI activity. Materials and methods – Serum samples were obtained every 3 months from 24 patients treated with 8×106 U of IFN beta‐1b every other day (treatment group) and from 21 patients without any immunomodulatory therapy (control group) over a 15‐month observation period. The cytokine levels were measured by ELISA. Cranial MRI was performed every 6 months to determine the burden of disease of every patient. Results – In the treatment group we found an obvious increase of sTNF‐R1 and sTNF‐R2 (P<0.001) and relatively stable serum levels of TNF‐beta with no statistical significance (P=0.56). In the control group, sTNF‐R1 showed a significant decrease (P<0.001) during the same observation period of 15 months. During the 15‐month observation period, the MRI‐responders group had significant larger mean AUC (area under the concentration‐time curve) values of sTNF‐R1 (P=0.04) and sTNF‐R2 (P=0.01) when compared to the group of MRI‐nonresponders. Conclusion – The present data suggest that IFN beta‐1b induces the expression and shedding of TNF‐R1 and TNF‐R2. The magnitude of an increase of sTNF‐Rs may be a marker for the effectiveness of treatment with IFN beta‐1b.
The objective of this study was to investigate the effect of interferon (IFN) beta-1b on the serum levels of soluble tumor necrosis factor receptor 1 (sTNF-R1) and sTNF-R2 in patients with multiple ...sclerosis (MS) in correlation with clinical and magnetic resonance image (MRI) activity. Serum samples were obtained every 3 months from 24 patients treated with 8 x 10(6) U of IFN beta-1b every other day (treatment group) and from 21 patients without any immunomodulatory therapy (control group) over a 15-month observation period. The cytokine receptor levels were assessed by ELISA. Cranial MRI was performed every 6 months to determine the burden of disease. In the treatment group, the MRI responders had significantly larger mean values for the area under the concentration-time curve of sTNF-R1 (p = 0.04) and sTNF-R2 (p = 0.01) when compared to the MRI nonresponders during the 15-month observation period. With regard to an increase in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment, we observed a sensitivity of 33 and 58%, respectively, a specificity of 90 and 60%, respectively, and a positive predictive value of 80 and 64%, respectively, for MRI response during the 15-month observation period. A decrease in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment had a sensitivity of 40 and 20%, respectively, a specificity of 100 and 100%, respectively, and a positive predictive value of 100 and 100%, respectively, for further MRI nonresponse (during the 15-month observation period). The present data suggest that assessment of sTNF-Rs may contribute to the identification of subgroups of patients who are likely to respond better than others to treatment with IFN beta-1b. This could help to establish a cost-effective prescription pattern for this expensive treatment, which is of importance for the future management of patients with MS.
A pseudoaneurysm is caused by an extravasal hematoma after vessel injury. Persistent blood supply via the afferent artery can lead to aneurysm growth with potential rupture of the lesion. We present ...a case of a 27-year-old man who developed three independent pseudoaneurysms after insertion of percutaneous distal locking bolts for static locking of an intramedullary femur nail. Color-coded Doppler sonography and intraarterial subtraction angiography were used to detect the lesion. Successful treatment consisted of endovascular embolization (coiling) with injection of a platinum coil into the aneurysm's supplying vessel. Pseudoaneurysm after fracture or fracture fixation represents a rare complication, but the risk of acute bleeding by pseudoaneurysm rupture should not be neglected.
